Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-08-08
2006-08-08
Woitach, Joseph (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093200, C424S093210, C604S508000
Reexamination Certificate
active
07087582
ABSTRACT:
The present invention provides a combination including a double-balloon catheter and a nucleic acid encoding the cyclin dependent kinase inhibitor p21. The nucleic acid may also encode HLA-B7, an immunotherapeutic agent, a cytokine or a prodrug converting enzyme.
REFERENCES:
patent: 5652225 (1997-07-01), Isner
patent: 5672508 (1997-09-01), Gyuris et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5863904 (1999-01-01), Nabel et al.
patent: 6057300 (2000-05-01), Nabel et al.
patent: 6218372 (2001-04-01), Nabel et al.
patent: 7-502651 (1995-03-01), None
patent: 10-506526 (1998-06-01), None
patent: 10-507626 (1998-07-01), None
patent: 10-512559 (1998-12-01), None
patent: 11-506315 (1999-06-01), None
patent: WO 94/09135 (1994-04-01), None
patent: WO 94/24297 (1994-10-01), None
patent: WO 95/06486 (1995-03-01), None
patent: WO 95/13375 (1995-05-01), None
patent: WO 95/18824 (1995-07-01), None
patent: WO 96/25507 (1996-08-01), None
Nabel et al. Science, 1990, 249: 1285-1288.
Xiong et al. Nature, 1993, 366: 701-704.
Mirriam-Webster's Collegiate Dictionary (1997) 10thEd., Merriam Webster, Inc., p. 228.
Eastham, et al. (1995) “In Vivo Gene Therapy with p53 or p21 Adenovirus for Prostate Cancer”, Cancer Research, 55: 5151-55.
Indolfi et al, Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo,Nature Medicine,1:(6) 541-5, Jun. 1995.
Junjie Chen, et al., “Separate Domains of p21 Involved in the Inhibition of CDK Kinase and PCNA”,Nature, vol. 374, pp. 386-388, Mar. 23, 1995.
Aldo Di Leonardo, et al., “DNA Damage Triggers a Prolonged P53-Dependent G1 Arrest and Long-Term Induction of CIP1 in Normal Human Fibroblasts”,Genes&Development,vol. 8, pp. 2540-2551, 1994.
Wafik S. El-Deiry, et al., “WAF1/CIP1 is Induced in P53-Mediated G1 Arrest and Apoptosis”,Cancer Research,vol. 54, pp. 1169-1174, Mar. 1, 1994.
Wafik S. El-Deiry, et al., “WAF1, A Potential Mediator of P53 Tumor Suppression”,Cell, vol. 75, pp. 817-825, Nov. 19, 1993.
Yong Gu, et al., “Inhibition of CDK2 Activity In Vivo by an Associated 20K Regulatory Subunit”,Nature, vol. 366, pp. 707-710, Dec. 16, 1993.
J. Wade Harper, et al., “The P21 CDK-Interacting Protein CIP1 is a Potent Inhibitor of G1 Cyclin-Dependent Kinases”,Cell, vol. 75, pp. 805-816, Nov. 19, 1993.
Rong Li, et al., “Differential Effects by the P21 CDK Inhibitor on PCNA-Dependent DNA Replication and Repair”,Nature, vol. 371, pp. 534-537, Oct. 6, 1994.
Yan Li, et al., “Cell Cycle Expression and P53 Regulation of the Cyclin-Dependent Kinase Inhibitor P21”,Oncogene, vol. 9, pp. 2261-2268, 1994.
Shou Waga, et al., “The P21 Inhibitor of Cyclin-Dependent Kinases Controls DNA Replication by Interaction with PCNA”,Nature, vol. 369, pp. 574-578, Jun. 16, 1994.
Yue Xiong, et al., “P21 is a Universal Inhibitor of Cyclin Kinases”,Nature, vol. 366, pp. 701-704, Dec. 16, 1993.
Hui Zhang, et al., “P21-containing Cyclin Kinases Exist in Both Active and Inactive States”,Genes&Development, vol. 8, pp. 1750-1758, 1994.
Kornelia Polyak et al., “Cloning of p27Kipl, a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals”,Cell, vol. 78, pp. 59-66, Jul. 15, 1994.
Hideo Toyoshima et al., “p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21”,Cell, vol. 78, pp. 67-74, Jul. 15, 1994.
Culver et al., “Gene Therapy for Cancer”,TIG,vol. 10, No. 5, 174-178 (1994).
Leslie A. Leinwand et al.,Trends Cardiovase. Med.,vol. 1, No. 7, pp. 271-275 (1991).
George Palade,Science, vol. 189, pp. 347-357 (Aug. 1975).
Bloom et al.,A Textbook of Histology,Eleventh Edition, p. 83, p. 279 and p. 51 (1986).
Richard N. Kitsis et al.,Proc. Natl. Acad. Sci.USA, vol. 88, pp. 4138-4142 (May 1991).
Eliav Barr et al.,Science,vol. 254, pp. 1507-1509 (Dec. 1991).
Hua Lin et al.,Circulation,vol. 82, pp. 2217-2221 (Dec. 1990).
Jyotsna Dhawan et al.,Science,vol. 254, pp. 1509-1512 (Dec. 1991).
Gyula Acsadi et al.,The New Biologists,vol. 3, No. 1, pp. 71-81 (Jan. 1991).
Peter M. Buttrick et al.,Circulation Research,vol. 70, No. 1, pp. 193-198 (Jan. 1992).
Gorman et al.,Sciencevol. 221, pp. 551-553 (1983).
Michael S. Parmacek et al.,The Journal of Biological Chemistry,vol. 265, No. 26, pp. 15970-15976 (1990).
Peter G. Anderson et al.,J. Cell Biochem,(Suppl.), vol. 13, Part E, p. 176 (1989).
T.A. Partridge et al., Nature, vol. 337, pp. 176-179 (Jan. 1989).
Jon A. Wolff et al.,Science,vol. 247, pp. 1465-1468 (Mar. 1990).
Leiden et al.,Circulation,vol. 82, p. 82 (1990) Abstract 0423.
Buttrick et al.,Circulation,vol. 82, p. 82 (1990) Abstract 0424.
Marshal,Science,269: 1050-1055, 1995.
Miller et al.,FASEB J.,9: 190-199, 1995.
Culver et al.,TIG,10(5), 174-178, 1994.
Hodgson,Exp. Opin. Ther. Pat.,5(5): 459-468, 1995.
Lafont et al.,Lancet,346: 1442-1443, 1995.
Etienne-Julan et al, The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker,Journal of General Virology73: 3251-3255, 1992.
Jolly, Viral vector systems for gene therapy, Cancer Gene therapy, 1:1,51-64, 1994.
Zakut et al, The tumor suppression function of p21 Waf is contained in its N-terminal half,Oncogene,11:393-395, Jul. 1995.
Chang, M. W. et al., “Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation on the Rat Carotid Artery Model of Balloon Angioplasty”Journal of Clinical Investigation, vol. 96, No. 5, pp. 2260-2268 (1995).
Yang,Z-Y et al., “Role of the p21 cyclin-dependent Kinase Inhibitor in Limiting Intimal Cell Proliferation in Response to Arterial Injury” Proc. Natl. Acad. Sci, vol. 93, No. 15, pp. 7905-7910 (1996).
Gallick, G.C. et al. “Expression of p21 RAS in Fresh Primary and Metastatic Human Colorectal Tumors”Proc. Natl. Acad. Sci. vol. 82, No. 6, pp. 1795-1799 (1985).
Nabel Elizabeth G.
Nabel Gary J.
Yang Zhi-yong
Brinks Hofer Gilson & Lione
Kelly Robert M.
Regents of the University of Michigan
Woitach Joseph
LandOfFree
Combination for site-specifically transforming cells in vivo... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination for site-specifically transforming cells in vivo..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination for site-specifically transforming cells in vivo... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3679743